Twitter | Search | |
This is the legacy version of twitter.com. We will be shutting it down on 15 December 2020. Please switch to a supported browser or device. You can see a list of supported browsers in our Help Center.
AJ Kay
More evidence re: FDA approval of Remdesivir on 10/22 affected hospitalization volume: We aquired internal treatment protocol for a large, multi-hospital regional healthcare system: As of 11/3, Remdesivir is FIRST LINE treatment for patients hospitalized c/ C19...
Reply Retweet Like More
AJ Kay Nov 13
Replying to @AJKayWriter
This helps explain the recent increase in hospitalization numbers that are unmatched by either an increase in ICU census or increase in deaths, as illustrated by California C19 data, which shows a nadir in hospitalizations 2 days before FDA approval and subsequent increase...
Reply Retweet Like
AJ Kay Nov 13
Replying to @AJKayWriter
The inclination to sow panic about hospitalization numbers increasing needs to be tempered w/ context regarding "Why?" When there's only one FDA approved treatment, it requires hospitalization, and immidiately following approval, hospitalizations rise? That's important context.
Reply Retweet Like
Jordan Penick Nov 13
Replying to @AJKayWriter
Very much in line with the NIH's recommendations which truly baffles me. (You're clearing it up so now!) I saw this a few weeks ago & thought are we really not recommending ANY prescr drugs/OTC meds/vitamins/care at all until it requires hospitilization?
Reply Retweet Like
AJ Kay Nov 13
Replying to @jordanb01
It is EXACTLY in line with the NIH's recc... Its not unreasonable to extrapolate this trend all over the country.
Reply Retweet Like
Patrick Madden Nov 13
Replying to @AJKayWriter
Strange question- with the Eli Lilly (and Regeneron) drugs entering the mix and available as outpatient treatment does this change these facts on the ground meaning the patients getting Remedisvir might in some cases be given the antibodies outside hospitals instead?
Reply Retweet Like
AJ Kay Nov 13
Replying to @TheSportsJD
It depends and we will see. Remdes can be justified given its exclusive FDA approval. There will be less profit-driven institutions favoring outcome over revenue who practice more discretion with EUA tx. But large-system protocol can easily show pref for the FDA approved Rx.
Reply Retweet Like
rmac Nov 14
Replying to @AJKayWriter
did something change with the efficacy of remdesivir? I thought the results were marginal. Although interestingly AHA did create a new ICD-10-PCS code to specifically capture it's admin, and that code was effective 10/1
Reply Retweet Like
AJ Kay Nov 14
Replying to @ramcct
Hospital admin are interested in both outcomes and revenue. Being the only FDA approved tx and a well-compensated protocol are both incentives to prioritize its use. They’ve had an EUA since summer, but the FDA approval didn’t happen until the end of October.
Reply Retweet Like
AJ Kay Nov 13
Replying to @little_wrong
We know that the HCQ protocol has been explicitly rejected, despite evidence of efficacy.
Reply Retweet Like